IP Library Granted Patent US 11,896,721
Granted Patent B2
US 11,896,721 · App. 16/864,715 · Granted Feb 13, 2024

Multiparticulate L-carnitine compositions and related methods

Inventors: Syed M. Shah (Boca Raton, FL); Noreen Hassan (Boca Raton, FL)
Assignee: Société des Produits Nestlé S.A.
A61K9/5073A23L33/175A23P10/30A61K9/5026A61K9/5031A61K9/5042A61K31/205A61K31/225A23V2002/00A61K9/5078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,896,721
App. No.
16/864,715
Granted
Feb 13, 2024
Kind
B2
Abstract

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

Claims (6)

1. An oral controlled-release multiparticulate dosage form comprising an L-carnitine carried on a plurality of individually enteric coated particulates that independently disperse in a person's stomach after oral ingestion and travel through the stomach and past a pyloric sphincter, the individually enteric coated particulates comprising (a) a spheronized extrudate solid core including the L-carnitine intermixed with a pharmaceutically acceptable binder and a pharmaceutically acceptable filler and (b) an enteric coating over the solid core, a predominant component of the enteric coating being an enteric polymer, wherein the solid core is spheroidal and comprises 30%-90% w/w of the L-carnitine, 15%-70% w/w microcrystalline cellulose filler, and 0.5%-1.5% w/w hydroxypropyl methylcellulose binder.

2. The dosage form of claim 1 , wherein the L-carnitine is selected from at least one of L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine.

3. The dosage form of claim 1 , wherein the enteric polymer is selected from at least one of methacrylic acid co-polymer, cellulose acetate phthalate, and polyvinyl acetate phthalate.

4. The dosage form of claim 1 , wherein an average diameter of the individually enteric coated particulates is about 0.1-3 mm.

5. The dosage form of claim 1 , further comprising a cellulosic water soluble polymer subcoating over the solid core and under the enteric coating.

6. The dosage form of claim 1 , further comprising polysorbate 80 effective to enhance permeation of the L-carnitine in a person's tissue.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2020
From: PHYSICIAN'S SEAL, LLC
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054516/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2020
From: SHAH, SYED M.; HASSAN, NOREEN
To: PHYSICIAN'S SEAL, LLC
Reel/Frame 052561/0754 →
Continuity (5)
Continuation 16121245 · Sep 4, 2018
Division 14476152 · Sep 3, 2014
Continuation 13490198 · Jun 6, 2012
Provisional Application 61494053 · Jun 7, 2011
Related Publication 20200253882A1 · Aug 13, 2020